<![CDATA[ Regulatory/Legal RSS Feed]]> https://www.pharma-iq.com/rss/categories/regulatorylegal en Tue, 19 Mar 2024 03:52:08 +0000 <![CDATA[The five IDMP standards and upcoming changes to data submission]]> https://www.pharma-iq.com/regulatorylegal/articles/the-five-idmp-standards-and-upcoming-changes-to-data-submission?utm_medium=RSS https://www.pharma-iq.com/regulatorylegal/articles/the-five-idmp-standards-and-upcoming-changes-to-data-submission?utm_medium=RSS Tue, 29 Aug 2023 15:18:18 +0000 <![CDATA[How to navigate UK and EU quality regulations in a post-Brexit world]]> https://www.pharma-iq.com/regulatorylegal/whitepapers/how-to-navigate-uk-and-eu-quality-regulations-in-a-post-brexit-world?utm_medium=RSS https://www.pharma-iq.com/regulatorylegal/whitepapers/how-to-navigate-uk-and-eu-quality-regulations-in-a-post-brexit-world?utm_medium=RSS Tue, 29 Aug 2023 15:20:59 +0000 <![CDATA[Keeping tabs on Covid-19: Taiwan’s vaccine feud with China ends and South Africa...]]> https://www.pharma-iq.com/pre-clinical-discovery-and-development/articles/keeping-tabs-covid-19-taiwans-vaccine-feud-china-ends-south-africa-registers-17000-new-covid-19-cases?utm_medium=RSS https://www.pharma-iq.com/pre-clinical-discovery-and-development/articles/keeping-tabs-covid-19-taiwans-vaccine-feud-china-ends-south-africa-registers-17000-new-covid-19-cases?utm_medium=RSS Tue, 29 Aug 2023 15:18:12 +0000 <![CDATA[Anti-counterfeiting playbook for small- and mid-sized pharma companies]]> https://www.pharma-iq.com/regulatorylegal/whitepapers/anti-counterfeiting-playbook-small-mid-sized-pharma-companies?utm_medium=RSS https://www.pharma-iq.com/regulatorylegal/whitepapers/anti-counterfeiting-playbook-small-mid-sized-pharma-companies?utm_medium=RSS Tue, 29 Aug 2023 15:20:59 +0000 <![CDATA[FDA grants accelerated approval for first Alzheimer’s disease treatment]]> https://www.pharma-iq.com/regulatorylegal/news/fda-grants-accelerated-approval-first-alzheimers-disease-treatment?utm_medium=RSS https://www.pharma-iq.com/regulatorylegal/news/fda-grants-accelerated-approval-first-alzheimers-disease-treatment?utm_medium=RSS Tue, 29 Aug 2023 15:20:59 +0000 <![CDATA[A regulatory perspective on real-world data and real-world evidence]]> https://www.pharma-iq.com/regulatorylegal/articles/regulatory-perspective-real-world-data-real-world-evidence?utm_medium=RSS https://www.pharma-iq.com/regulatorylegal/articles/regulatory-perspective-real-world-data-real-world-evidence?utm_medium=RSS Tue, 29 Aug 2023 15:20:59 +0000 <![CDATA[Keeping tabs on Covid-19: AstraZeneca hoping to win US approval for their Covid-...]]> https://www.pharma-iq.com/pre-clinical-discovery-and-development/articles/keeping-tabs-covid-19-astrazeneca-win-us-approval-jj-resumes-vaccine-roll-out-europe?utm_medium=RSS https://www.pharma-iq.com/pre-clinical-discovery-and-development/articles/keeping-tabs-covid-19-astrazeneca-win-us-approval-jj-resumes-vaccine-roll-out-europe?utm_medium=RSS Tue, 29 Aug 2023 15:20:22 +0000 <![CDATA[How to implement an anti-counterfeiting strategy earlier into the drug developme...]]> https://www.pharma-iq.com/regulatorylegal/whitepapers/implement-anti-counterfeiting-strategy-drug-development-process?utm_medium=RSS https://www.pharma-iq.com/regulatorylegal/whitepapers/implement-anti-counterfeiting-strategy-drug-development-process?utm_medium=RSS Tue, 29 Aug 2023 15:20:59 +0000 <![CDATA[Philippines FDA to speed up Covid-19 clinical trial approval decisions by 50 per...]]> https://www.pharma-iq.com/regulatorylegal/articles/philippines-fda-speed-covid-19-clinical-trial-approval-decisions-50-per-cent?utm_medium=RSS https://www.pharma-iq.com/regulatorylegal/articles/philippines-fda-speed-covid-19-clinical-trial-approval-decisions-50-per-cent?utm_medium=RSS Tue, 29 Aug 2023 15:20:22 +0000 <![CDATA[The state of data integrity and data security in life sciences]]> https://www.pharma-iq.com/informatics/reports/the-state-data-integrity-data-security-life-sciences?utm_medium=RSS https://www.pharma-iq.com/informatics/reports/the-state-data-integrity-data-security-life-sciences?utm_medium=RSS Tue, 29 Aug 2023 15:18:12 +0000 <![CDATA[Patent and know-how licensing: Going beyond the textbooks]]> https://www.pharma-iq.com/regulatorylegal/articles/patent-and-know-how-licensing-how-to-go-beyond-the-textbooks?utm_medium=RSS https://www.pharma-iq.com/regulatorylegal/articles/patent-and-know-how-licensing-how-to-go-beyond-the-textbooks?utm_medium=RSS Tue, 29 Aug 2023 15:20:59 +0000 <![CDATA[US Launch: Five litigation strategies European biosimilar developers should know]]> https://www.pharma-iq.com/regulatorylegal/articles/us-launch-five-litigation-strategies-european-biosimilar-developers-should-know?utm_medium=RSS https://www.pharma-iq.com/regulatorylegal/articles/us-launch-five-litigation-strategies-european-biosimilar-developers-should-know?utm_medium=RSS Tue, 29 Aug 2023 15:20:59 +0000